Equities research analysts predict that Hologic, Inc. (NASDAQ:HOLX) will report earnings per share (EPS) of $0.49 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Hologic’s earnings, with the lowest EPS estimate coming in at $0.48 and the highest estimate coming in at $0.49. Hologic posted earnings per share of $0.52 during the same quarter last year, which suggests a negative year-over-year growth rate of 5.8%. The business is scheduled to announce its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Hologic will report full year earnings of $2.01 per share for the current fiscal year, with EPS estimates ranging from $2.00 to $2.02. For the next year, analysts expect that the business will report earnings of $2.18 per share, with EPS estimates ranging from $2.06 to $2.28. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Hologic.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm’s revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.51 earnings per share.

A number of brokerages have recently issued reports on HOLX. Stifel Nicolaus raised their price objective on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. Jefferies Group LLC set a $49.00 target price on Hologic and gave the stock a “buy” rating in a research note on Sunday, May 28th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 target price on shares of Hologic in a research note on Friday, July 14th. Bank of America Corporation reaffirmed a “neutral” rating and set a $48.00 target price (up previously from $44.00) on shares of Hologic in a research note on Friday, July 21st. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $53.00 target price (up previously from $50.00) on shares of Hologic in a research note on Monday, July 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $48.64.

Shares of Hologic (HOLX) traded up 2.17% during mid-day trading on Friday, hitting $38.20. 3,819,623 shares of the company’s stock were exchanged. The company has a market capitalization of $10.71 billion, a price-to-earnings ratio of 14.23 and a beta of 0.90. The firm has a 50 day moving average price of $43.73 and a 200-day moving average price of $42.89. Hologic has a 52 week low of $35.15 and a 52 week high of $46.80.

In other news, Director Lawrence M. Levy sold 2,960 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $44.54, for a total value of $131,838.40. Following the transaction, the director now owns 45,634 shares in the company, valued at $2,032,538.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elaine Ullian sold 8,849 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $45.28, for a total value of $400,682.72. Following the completion of the transaction, the director now owns 23,810 shares in the company, valued at approximately $1,078,116.80. The disclosure for this sale can be found here. Insiders sold 60,627 shares of company stock valued at $2,632,911 in the last three months. Insiders own 0.79% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of HOLX. Teachers Advisors LLC raised its position in Hologic by 28.8% in the fourth quarter. Teachers Advisors LLC now owns 643,547 shares of the medical equipment provider’s stock worth $25,819,000 after buying an additional 143,960 shares in the last quarter. Chevy Chase Trust Holdings Inc. raised its position in Hologic by 3.6% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 240,769 shares of the medical equipment provider’s stock worth $10,245,000 after buying an additional 8,289 shares in the last quarter. Gulf International Bank UK Ltd raised its position in Hologic by 1.5% in the first quarter. Gulf International Bank UK Ltd now owns 74,164 shares of the medical equipment provider’s stock worth $3,155,000 after buying an additional 1,100 shares in the last quarter. National Pension Service raised its position in Hologic by 55,168.1% in the first quarter. National Pension Service now owns 244,285 shares of the medical equipment provider’s stock worth $10,433,000 after buying an additional 243,843 shares in the last quarter. Finally, Fox Run Management L.L.C. raised its position in Hologic by 117.2% in the first quarter. Fox Run Management L.L.C. now owns 12,600 shares of the medical equipment provider’s stock worth $536,000 after buying an additional 6,800 shares in the last quarter. Institutional investors own 94.46% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Hologic, Inc. (NASDAQ:HOLX) Will Post Earnings of $0.49 Per Share” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/zacks-analysts-anticipate-hologic-inc-nasdaqholx-will-post-earnings-of-0-49-per-share/1476162.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.